Which has better valuation and earnings, VOR or QTTB?

Q32 Bio has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Q32 Bio $53.74M 4.46 $29.82M $2.66 5.32

Is VOR or QTTB more profitable?

Q32 Bio's return on equity of 149.23% beat Vor Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Q32 Bio N/A 149.23% 34.50%

Which has higher valuation and earnings, IVA or QTTB?

Q32 Bio has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 145.44 -$400.67M N/A N/A Q32 Bio $53.74M 4.46 $29.82M $2.66 5.32

Is IVA or QTTB more profitable?

Q32 Bio's return on equity of 149.23% beat Inventiva's return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Q32 Bio N/A 149.23% 34.50%

Which has preferable valuation and earnings, ZVRA or QTTB?

Zevra Therapeutics has higher revenue and earnings than Q32 Bio. Q32 Bio is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zevra Therapeutics $106.47M 7.78 $83.23M $1.99 7.04 Q32 Bio $53.74M 4.46 $29.82M $2.66 5.32

Which has stronger valuation & earnings, QTTB or CYRX?

CryoPort has higher revenue and earnings than Q32 Bio. Q32 Bio is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Q32 Bio $53.74M 4.46 $29.82M $2.66 5.32 CryoPort $182.94M 4.49 $78.30M $1.35 12.06

Is QTTB or CYRX more profitable?

CryoPort has a net margin of 41.57% compared to Q32 Bio's net margin of 0.00%. Q32 Bio's return on equity of 149.23% beat CryoPort's return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 149.23% 34.50% CryoPort 41.57% -7.92% -4.79%

Is QTTB or AURA more profitable?

Q32 Bio's return on equity of 149.23% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 149.23% 34.50% Aura Biosciences N/A -78.12% -64.08%

Q32 Bio (QTTB) Competitors

$14.14 +0.97 (+7.37%)

Closing price 04:00 PM Eastern

Extended Trading

$14.52 +0.39 (+2.72%)

As of 07:16 PM Eastern

Compare

QTTB vs. VOR, IVA, ZVRA, CYRX, and AURA

Should you buy Q32 Bio stock or one of its competitors? MarketBeat compares Q32 Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Q32 Bio include Vor Biopharma (VOR), Inventiva (IVA), Zevra Therapeutics (ZVRA), CryoPort (CYRX), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry.

How does Q32 Bio compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Q32 Bio (NASDAQ:QTTB) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by company insiders. Comparatively, 34.5% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Vor Biopharma had 1 more articles in the media than Q32 Bio. MarketBeat recorded 2 mentions for Vor Biopharma and 1 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.89 beat Vor Biopharma's score of 0.94 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Vor Biopharma	Positive
Q32 Bio	Very Positive

Q32 Bio has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Q32 Bio	$53.74M	4.46	$29.82M	$2.66	5.32

Vor Biopharma currently has a consensus price target of $42.25, suggesting a potential upside of 127.15%. Q32 Bio has a consensus price target of $13.50, suggesting a potential downside of 4.53%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Q32 Bio's return on equity of 149.23% beat Vor Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Q32 Bio	N/A	149.23%	34.50%

Vor Biopharma has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Summary

Vor Biopharma beats Q32 Bio on 7 of the 12 factors compared between the two stocks.

How does Q32 Bio compare to Inventiva?

Inventiva (NASDAQ:IVA) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Q32 Bio has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	145.44	-$400.67M	N/A	N/A
Q32 Bio	$53.74M	4.46	$29.82M	$2.66	5.32

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 34.5% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Q32 Bio's return on equity of 149.23% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Q32 Bio	N/A	149.23%	34.50%

In the previous week, Inventiva had 1 more articles in the media than Q32 Bio. MarketBeat recorded 2 mentions for Inventiva and 1 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.89 beat Inventiva's score of 0.94 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Inventiva	Positive
Q32 Bio	Very Positive

Inventiva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

Inventiva presently has a consensus price target of $16.56, indicating a potential upside of 366.35%. Q32 Bio has a consensus price target of $13.50, indicating a potential downside of 4.53%. Given Inventiva's stronger consensus rating and higher possible upside, research analysts clearly believe Inventiva is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Inventiva and Q32 Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Q32 Bio compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Zevra Therapeutics has a net margin of 101.58% compared to Q32 Bio's net margin of 0.00%. Q32 Bio's return on equity of 149.23% beat Zevra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Q32 Bio	N/A	149.23%	34.50%

In the previous week, Zevra Therapeutics had 2 more articles in the media than Q32 Bio. MarketBeat recorded 3 mentions for Zevra Therapeutics and 1 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.89 beat Zevra Therapeutics' score of 0.63 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Zevra Therapeutics	Positive
Q32 Bio	Very Positive

Zevra Therapeutics presently has a consensus target price of $29.29, indicating a potential upside of 109.03%. Q32 Bio has a consensus target price of $13.50, indicating a potential downside of 4.53%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Zevra Therapeutics is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Zevra Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Q32 Bio. Q32 Bio is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	7.78	$83.23M	$1.99	7.04
Q32 Bio	$53.74M	4.46	$29.82M	$2.66	5.32

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 34.5% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Zevra Therapeutics beats Q32 Bio on 11 of the 16 factors compared between the two stocks.

How does Q32 Bio compare to CryoPort?

Q32 Bio (NASDAQ:QTTB) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 34.5% of Q32 Bio shares are held by insiders. Comparatively, 10.0% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CryoPort has a net margin of 41.57% compared to Q32 Bio's net margin of 0.00%. Q32 Bio's return on equity of 149.23% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	149.23%	34.50%
CryoPort	41.57%	-7.92%	-4.79%

Q32 Bio currently has a consensus target price of $13.50, suggesting a potential downside of 4.53%. CryoPort has a consensus target price of $15.11, suggesting a potential downside of 7.18%. Given Q32 Bio's higher probable upside, equities research analysts clearly believe Q32 Bio is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

CryoPort has higher revenue and earnings than Q32 Bio. Q32 Bio is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	4.46	$29.82M	$2.66	5.32
CryoPort	$182.94M	4.49	$78.30M	$1.35	12.06

Q32 Bio has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

In the previous week, CryoPort had 4 more articles in the media than Q32 Bio. MarketBeat recorded 5 mentions for CryoPort and 1 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.89 beat CryoPort's score of 1.03 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Q32 Bio	Very Positive
CryoPort	Positive

Summary

CryoPort beats Q32 Bio on 10 of the 16 factors compared between the two stocks.

How does Q32 Bio compare to Aura Biosciences?

Q32 Bio (NASDAQ:QTTB) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Q32 Bio currently has a consensus target price of $13.50, suggesting a potential downside of 4.53%. Aura Biosciences has a consensus target price of $20.50, suggesting a potential upside of 197.97%. Given Aura Biosciences' higher probable upside, analysts plainly believe Aura Biosciences is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Q32 Bio and Q32 Bio both had 1 articles in the media. Q32 Bio's average media sentiment score of 1.89 beat Aura Biosciences' score of 1.87 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Q32 Bio	Very Positive
Aura Biosciences	Very Positive

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by company insiders. Comparatively, 6.3% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Q32 Bio has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Q32 Bio has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	4.46	$29.82M	$2.66	5.32
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Q32 Bio's return on equity of 149.23% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	149.23%	34.50%
Aura Biosciences	N/A	-78.12%	-64.08%

Summary

Q32 Bio beats Aura Biosciences on 10 of the 13 factors compared between the two stocks.

Get Q32 Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QTTB vs. The Competition

Export

Metric	Q32 Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$239.81M	$3.65B	$6.84B	$12.43B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	5.32	21.29	25.83	24.36
Price / Sales	4.46	195.79	511.51	84.16
Price / Cash	8.69	62.10	29.09	36.93
Price / Book	4.15	8.71	10.98	6.49
Net Income	$29.82M	$23.87M	$3.57B	$336.61M
7 Day Performance	11.78%	4.23%	3.06%	0.90%
1 Month Performance	27.96%	1.71%	0.72%	-0.36%
1 Year Performance	875.17%	69.92%	36.82%	31.26%

Q32 Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QTTB Q32 Bio	3.6905 of 5 stars	$14.14 +7.4%	$13.50 -4.5%	+808.3%	$239.81M	$53.74M	5.32	39	Positive News
VOR Vor Biopharma	2.3473 of 5 stars	$14.85 -0.6%	$42.25 +184.5%	-24.1%	$804.66M	N/A	N/A	140	News Coverage
IVA Inventiva	2.8038 of 5 stars	$3.71 +5.7%	$16.56 +346.2%	+12.5%	$770.60M	$5.07M	N/A	100	Gap Up High Trading Volume
ZVRA Zevra Therapeutics	4.4204 of 5 stars	$13.00 +2.8%	$29.29 +125.3%	+50.2%	$768.56M	$106.47M	6.53	20
CYRX CryoPort	3.826 of 5 stars	$14.76 -0.1%	$15.11 +2.4%	+115.9%	$743.93M	$182.94M	10.93	1,186	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QTTB) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Q32 Bio (QTTB) Competitors

QTTB vs. VOR, IVA, ZVRA, CYRX, and AURA

How does Q32 Bio compare to Vor Biopharma?

Summary

How does Q32 Bio compare to Inventiva?

Summary

How does Q32 Bio compare to Zevra Therapeutics?

Summary

How does Q32 Bio compare to CryoPort?

Summary

How does Q32 Bio compare to Aura Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB vs. The Competition

Q32 Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Q32 Bio (QTTB) Competitors

QTTB vs. VOR, IVA, ZVRA, CYRX, and AURA

How does Q32 Bio compare to Vor Biopharma?

Do insiders and institutionals hold more shares of VOR or QTTB?

Does the media favor VOR or QTTB?

Which has better valuation and earnings, VOR or QTTB?

Do analysts rate VOR or QTTB?

Is VOR or QTTB more profitable?

Which has more volatility and risk, VOR or QTTB?

Summary

How does Q32 Bio compare to Inventiva?

Which has higher valuation and earnings, IVA or QTTB?

Do institutionals and insiders believe in IVA or QTTB?

Is IVA or QTTB more profitable?

Does the media favor IVA or QTTB?

Which has more risk & volatility, IVA or QTTB?

Do analysts recommend IVA or QTTB?

Summary

How does Q32 Bio compare to Zevra Therapeutics?

Is ZVRA or QTTB more profitable?

Does the media favor ZVRA or QTTB?

Do analysts rate ZVRA or QTTB?

Which has more volatility & risk, ZVRA or QTTB?

Which has preferable valuation and earnings, ZVRA or QTTB?

Do institutionals and insiders believe in ZVRA or QTTB?

Summary

How does Q32 Bio compare to CryoPort?

Do institutionals and insiders have more ownership in QTTB or CYRX?

Is QTTB or CYRX more profitable?

Do analysts rate QTTB or CYRX?

Which has stronger valuation & earnings, QTTB or CYRX?

Which has more volatility and risk, QTTB or CYRX?

Does the media refer more to QTTB or CYRX?

Summary

How does Q32 Bio compare to Aura Biosciences?

Do analysts recommend QTTB or AURA?

Does the media favor QTTB or AURA?

Do institutionals & insiders have more ownership in QTTB or AURA?

Which has more volatility and risk, QTTB or AURA?

Which has higher valuation and earnings, QTTB or AURA?

Is QTTB or AURA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB vs. The Competition

Q32 Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools